Glenn D. Braunstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Glenn D. Braunstein has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
C. Noel Bairey Merz
Cedars-Sinai Research Institute
2 shared publicationsFnu Deepinder
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
2 shared publicationsMaura Paul-Labrador
Cedars-Sinai Research Institute
2 shared publicationsAkshay Buch
Warner Chilcott Pharmaceuticas Inc , Mason, OH , USA
1 shared publicationAlan D Waxman
Nuclear Medicine, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048
1 shared publicationB. Delia Johnson
Graduate School of Public Health, University of Pittsburgh (B.D.J.), Pittsburgh, Pennsylvania 15261
1 shared publication
Latest Publications
- Open Access
- 24 June 2014
- Published by Informa Healthcare in Expert Opinion on Therapeutic Targets
- Vol. 18 (9) , 979-982
LAMC2 as a therapeutic target for cancers
Cancer is the leading cause of morbidity and mortality in developed countries and the second major cause of death in developing countries. Laminins are crucial proteins in the basal lamina (one of the layers of the basement membrane), and these form a protein network that influences both normal and transformed cell differentiation, migration and adhesion, as well as phenotype and survival. The basement membranes act as a mechanical barrier to tumor growth, but these molecules, including laminins, are also important autocrine factors produced by cancers to promote tumorigenesis. Several studies in cancers have shown the importance of LAMC2, a laminin component. The elevated expression of LAMC2 on cancer cells appears to drive tumorigenesis through its interactions with several cell-surface receptors including α6β4 and α3β1 integrins and EGFRs. The accumulating evidence indicates that LAMC2-mediated signaling network plays an important role in the progression, migration and invasion of multiple types of can...
- 24 June 2014
- Published by Informa Healthcare in Expert Opinion on Therapeutic Targets
- Vol. 18 (9) , 979-982
Open AccessLAMC2 as a therapeutic target for cancers
Cancer is the leading cause of morbidity and mortality in developed countries and the second major cause of death in developing countries. Laminins are crucial proteins in the basal lamina (one of the layers of the basement membrane), and these form a protein network that influences both normal and transformed cell differentiation, migration and adhesion, as well as phenotype and survival. The basement membranes act as a mechanical barrier to tumor growth, but these molecules, including laminins, are also important autocrine factors produced by cancers to promote tumorigenesis. Several studies in cancers have shown the importance of LAMC2, a laminin component. The elevated expression of LAMC2 on cancer cells appears to drive tumorigenesis through its interactions with several cell-surface receptors including α6β4 and α3β1 integrins and EGFRs. The accumulating evidence indicates that LAMC2-mediated signaling network plays an important role in the progression, migration and invasion of multiple types of can...
- Open Access
- 1 January 2014
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 60 (1) , 18-21
The Long Gestation of the Modern Home Pregnancy Test
- 1 January 2014
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 60 (1) , 18-21
Open AccessThe Long Gestation of the Modern Home Pregnancy Test
- 6 August 2012
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 11 (5) , 779-795
Drug-induced gynecomastia: an evidence-based review
Introduction: Drugs are estimated to cause about 10 – 25% of all cases of gynecomastia. Over the course of several decades, multiple medications have been implicated in the development of gynecomastia mostly in the form of case reports and case series. However, these reports suffer from a multitude of deficiencies, including poor quality of evidence. Areas covered: Studies were selected for this review by performing an extensive electronic and hand-search using BIOSIS, EMBASE and Medline, from 1940 to present, for all reported drug associations of gynecomastia and their possible pathophysiology. Quality of evidence was assessed on a three-point scale: good, fair and poor, and each of the drugs reported to cause gynecomastia was assigned a level of strength. The pathophysiology of gynecomastia is also discussed in detail for each of the drugs found to have a good or fair evidence of association with gynecomastia. Expert opinion: Most of the reported drug–gynecomastia associations were based on poor quality evidence. The drugs definitely associated with the onset of gynecomastia are spironolactone, cimetidine, ketoconazole, hGH, estrogens, hCG, anti-androgens, GnRH analogs and 5-α reductase inhibitors. Medications probably associated with gynecomastia include risperidone, verapamil, nifedipine, omeprazole, alkylating agents, HIV medications (efavirenz), anabolic steroids, alcohol and opioids.
- 6 August 2012
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 11 (5) , 779-795
Drug-induced gynecomastia: an evidence-based review
Introduction: Drugs are estimated to cause about 10 – 25% of all cases of gynecomastia. Over the course of several decades, multiple medications have been implicated in the development of gynecomastia mostly in the form of case reports and case series. However, these reports suffer from a multitude of deficiencies, including poor quality of evidence. Areas covered: Studies were selected for this review by performing an extensive electronic and hand-search using BIOSIS, EMBASE and Medline, from 1940 to present, for all reported drug associations of gynecomastia and their possible pathophysiology. Quality of evidence was assessed on a three-point scale: good, fair and poor, and each of the drugs reported to cause gynecomastia was assigned a level of strength. The pathophysiology of gynecomastia is also discussed in detail for each of the drugs found to have a good or fair evidence of association with gynecomastia. Expert opinion: Most of the reported drug–gynecomastia associations were based on poor quality evidence. The drugs definitely associated with the onset of gynecomastia are spironolactone, cimetidine, ketoconazole, hGH, estrogens, hCG, anti-androgens, GnRH analogs and 5-α reductase inhibitors. Medications probably associated with gynecomastia include risperidone, verapamil, nifedipine, omeprazole, alkylating agents, HIV medications (efavirenz), anabolic steroids, alcohol and opioids.
- 1 March 2012
- Published by SAGE Publications in Journal of Women's Health
- Vol. 21 (3) , 281-284
Red Versus White Wine as a Nutritional Aromatase Inhibitor in Premenopausal Women: A Pilot Study
Background: An increased risk of breast cancer is associated with alcohol consumption; however, it is controversial whether red wine increases this risk. Aromatase inhibitors (AIs) prevent the conversion of androgens to estrogen and occur naturally in grapes, grape juice, and red, but not white wine. We tested whether red wine is a nutritional AI in premenopausal women. Methods: In a cross-over design, 36 women (mean age [SD], 36 [8] years) were assigned to 8 ounces (237 mL) of red wine daily then white wine for 1 month each, or the reverse. Blood was collected twice during the menstrual cycle for measurement of estradiol (E2), estrone (E1), androstenedione (A), total and free testosterone (T), sex hormone binding globulin (SHBG), luteinizing hormone (LH), and follicle stimulating hormone (FSH). Results: Red wine demonstrated higher free T vs. white wine (mean difference 0.64 pg/mL [0.2 SE], p =0.009) and lower SHBG (mean difference −5.0 nmol/L [1.9 SE], p =0.007). E2 levels were lower in red vs. white wine but not statistically significant. LH was significantly higher in red vs. white wine (mean difference 2.3 mIU/mL [1.3 SE], p =0.027); however, FSH was not. Conclusion: Red wine is associated with significantly higher free T and lower SHBG levels, as well as a significant higher LH level vs. white wine in healthy premenopausal women. These data suggest that red wine is a nutritional AI and may explain the observation that red wine does not appear to increase breast cancer risk.
- 1 March 2012
- Published by SAGE Publications in Journal of Women's Health
- Vol. 21 (3) , 281-284
Red Versus White Wine as a Nutritional Aromatase Inhibitor in Premenopausal Women: A Pilot Study
Background: An increased risk of breast cancer is associated with alcohol consumption; however, it is controversial whether red wine increases this risk. Aromatase inhibitors (AIs) prevent the conversion of androgens to estrogen and occur naturally in grapes, grape juice, and red, but not white wine. We tested whether red wine is a nutritional AI in premenopausal women. Methods: In a cross-over design, 36 women (mean age [SD], 36 [8] years) were assigned to 8 ounces (237 mL) of red wine daily then white wine for 1 month each, or the reverse. Blood was collected twice during the menstrual cycle for measurement of estradiol (E2), estrone (E1), androstenedione (A), total and free testosterone (T), sex hormone binding globulin (SHBG), luteinizing hormone (LH), and follicle stimulating hormone (FSH). Results: Red wine demonstrated higher free T vs. white wine (mean difference 0.64 pg/mL [0.2 SE], p =0.009) and lower SHBG (mean difference −5.0 nmol/L [1.9 SE], p =0.007). E2 levels were lower in red vs. white wine but not statistically significant. LH was significantly higher in red vs. white wine (mean difference 2.3 mIU/mL [1.3 SE], p =0.027); however, FSH was not. Conclusion: Red wine is associated with significantly higher free T and lower SHBG levels, as well as a significant higher LH level vs. white wine in healthy premenopausal women. These data suggest that red wine is a nutritional AI and may explain the observation that red wine does not appear to increase breast cancer risk.
- 1 December 2011
- Published by SAGE Publications in Thyroid®
- Vol. 21 (12) , 1339-1342
Do Patients Gain Weight After Thyroidectomy for Thyroid Cancer?
Background: Patients who undergo thyroidectomy often complain of weight gain, which they frequently attribute to inadequate thyroid hormone replacement. To assess the weight changes associated with thyroid hormone replacement or suppressive therapy after thyroidectomy, we measured the weights of patients before and after thyroidectomy and compared them to the weights of euthyroid patients with thyroid nodules who were being followed for many years. Methods: The weights and heights of 67 women and 35 men who underwent total thyroidectomy for thyroid cancer were recorded before and for a mean of 8.3 years after thyroidectomy. All patients received either suppressive or replacement doses of levothyroxine. As a comparison group, 70 women and 22 men with goiter or thyroid nodules and were euthyroid had serial measurements of height and weight. They were followed for a mean of 7.6 years. The body mass index (BMI) and age-adjusted BMI percentiles were calculated. The weight, BMI, and BMI percentile changes were compared both unadjusted and adjusted for age, gender, thyrotropin (TSH) level, and duration between measurements. Results: At baseline, patients with thyroid nodules were older (mean 50.4 years) than those with thyroid cancer (mean 45.8 years). There were no significant differences in baseline weight, BMI, or BMI percentile. The baseline TSH levels were lower for patients with thyroid cancer (mean 0.8 mIU/L) than for those with nodules (mean 1.8 mIU/L) (p=0.002). There were no significant differences between the changes in weight, BMI, or BMI percentile from the start to the completion of the study whether unadjusted or after adjustment for age, gender, TSH, and duration of follow-up. Conclusions: Despite the perception of many patients that their thyroidectomy and thyroid hormone replacement or suppressive therapy is responsible for their subsequent weight gain, there were no significant differences in weight gain over time in comparison to a control group of euthyroid patients with thyroid nodules or goiter.
- 1 December 2011
- Published by SAGE Publications in Thyroid®
- Vol. 21 (12) , 1339-1342
Do Patients Gain Weight After Thyroidectomy for Thyroid Cancer?
Background: Patients who undergo thyroidectomy often complain of weight gain, which they frequently attribute to inadequate thyroid hormone replacement. To assess the weight changes associated with thyroid hormone replacement or suppressive therapy after thyroidectomy, we measured the weights of patients before and after thyroidectomy and compared them to the weights of euthyroid patients with thyroid nodules who were being followed for many years. Methods: The weights and heights of 67 women and 35 men who underwent total thyroidectomy for thyroid cancer were recorded before and for a mean of 8.3 years after thyroidectomy. All patients received either suppressive or replacement doses of levothyroxine. As a comparison group, 70 women and 22 men with goiter or thyroid nodules and were euthyroid had serial measurements of height and weight. They were followed for a mean of 7.6 years. The body mass index (BMI) and age-adjusted BMI percentiles were calculated. The weight, BMI, and BMI percentile changes were compared both unadjusted and adjusted for age, gender, thyrotropin (TSH) level, and duration between measurements. Results: At baseline, patients with thyroid nodules were older (mean 50.4 years) than those with thyroid cancer (mean 45.8 years). There were no significant differences in baseline weight, BMI, or BMI percentile. The baseline TSH levels were lower for patients with thyroid cancer (mean 0.8 mIU/L) than for those with nodules (mean 1.8 mIU/L) (p=0.002). There were no significant differences between the changes in weight, BMI, or BMI percentile from the start to the completion of the study whether unadjusted or after adjustment for age, gender, TSH, and duration of follow-up. Conclusions: Despite the perception of many patients that their thyroidectomy and thyroid hormone replacement or suppressive therapy is responsible for their subsequent weight gain, there were no significant differences in weight gain over time in comparison to a control group of euthyroid patients with thyroid nodules or goiter.
- 13 October 2011
- Published by Springer Nature
- p. 109-131
Staging Systems for Differentiated Thyroid Carcinomas
- 13 October 2011
- Published by Springer Nature
- p. 109-131
Staging Systems for Differentiated Thyroid Carcinomas
- 1 October 2011
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 8 (10) , 2924-2934
Testosterone Reference Ranges in Normally Cycling Healthy Premenopausal Women
Introduction At present, there are no well‐accepted reference ranges for serum testosterone concentrations in women. Aim The aim of this study was to determine the reference ranges for serum testosterone and sex hormone‐binding globulin (SHBG) in premenopausal women with normal menstrual cycles. Methods We measured serum total, free, and bioavailable testosterone and SHBG concentrations in 161 healthy, normally cycling women (18–49 years). Morning blood samples were collected during follicular, mid‐cycle, and luteal phases of the menstrual cycle and analyzed using validated methods. Mean, median, and weighted average hormone levels across menstrual cycle phases as well as percentiles for a typical 30‐year‐old woman were determined. Main Outcome Measures Age‐related serum levels of total, free, and bioavailable testosterone and SHBG levels in normally cycling premenopausal women. Results Serum testosterone concentrations exhibited an age‐related decline, whereas SHBG remained relatively stable across studied age ranges. Reference ranges for total, free, and bioavailable testosterone and SHBG were established using 5th and 95th percentiles. The estimated 5th and 95th percentiles for a 30‐year‐old woman were: testosterone, 15–46 ng/dL (520–1595 pmol/L); free testosterone, 1.2–6.4 pg/mL (4.16–22.2 pmol/L); calculated free testosterone, 1.3–5.6 pg/mL (4.5–19.4 pmol/L); bioavailable testosterone, 1.12–7.62 ng/dL (38.8–264.21 pmol/L); and SHBG 18–86 nmol/L. The variations of hormones and SHBG across menstrual cycle were consistent with previous literature. Conclusions Reference ranges for free, total, and bioavailable testosterone and SHBG were established in premenopausal women using validated immunoassays and an adequate number of subjects consistent with recommendations by the National Committee for Clinical Laboratory Standards. The increase in testosterone in the mid‐cycle period is relatively small compared with the overall variability, so these reference ranges can be applied irrespective of the day in the menstrual cycle the sample has been taken. Braunstein GD, Reitz RE, Buch A, Schnell D, and Caulfield MP. Testosterone reference ranges in normally cycling healthy premenopausal women. J Sex Med 2011;8:2924–2934.
- 1 October 2011
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 8 (10) , 2924-2934
Testosterone Reference Ranges in Normally Cycling Healthy Premenopausal Women
Introduction At present, there are no well‐accepted reference ranges for serum testosterone concentrations in women. Aim The aim of this study was to determine the reference ranges for serum testosterone and sex hormone‐binding globulin (SHBG) in premenopausal women with normal menstrual cycles. Methods We measured serum total, free, and bioavailable testosterone and SHBG concentrations in 161 healthy, normally cycling women (18–49 years). Morning blood samples were collected during follicular, mid‐cycle, and luteal phases of the menstrual cycle and analyzed using validated methods. Mean, median, and weighted average hormone levels across menstrual cycle phases as well as percentiles for a typical 30‐year‐old woman were determined. Main Outcome Measures Age‐related serum levels of total, free, and bioavailable testosterone and SHBG levels in normally cycling premenopausal women. Results Serum testosterone concentrations exhibited an age‐related decline, whereas SHBG remained relatively stable across studied age ranges. Reference ranges for total, free, and bioavailable testosterone and SHBG were established using 5th and 95th percentiles. The estimated 5th and 95th percentiles for a 30‐year‐old woman were: testosterone, 15–46 ng/dL (520–1595 pmol/L); free testosterone, 1.2–6.4 pg/mL (4.16–22.2 pmol/L); calculated free testosterone, 1.3–5.6 pg/mL (4.5–19.4 pmol/L); bioavailable testosterone, 1.12–7.62 ng/dL (38.8–264.21 pmol/L); and SHBG 18–86 nmol/L. The variations of hormones and SHBG across menstrual cycle were consistent with previous literature. Conclusions Reference ranges for free, total, and bioavailable testosterone and SHBG were established in premenopausal women using validated immunoassays and an adequate number of subjects consistent with recommendations by the National Committee for Clinical Laboratory Standards. The increase in testosterone in the mid‐cycle period is relatively small compared with the overall variability, so these reference ranges can be applied irrespective of the day in the menstrual cycle the sample has been taken. Braunstein GD, Reitz RE, Buch A, Schnell D, and Caulfield MP. Testosterone reference ranges in normally cycling healthy premenopausal women. J Sex Med 2011;8:2924–2934.
- 1 September 2011
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 6 (5) , 723-730
Gynecomastia: incidence, causes and treatment
Gynecomastia is a benign proliferation of glandular tissue of the breast in males. It is common during three phases in the age distribution curve: the neonatal period, puberty and senescence. An imbalance between estrogen and androgen action at the level of breast tissue is believed to be the underlying pathophysiology. Initial steps in the clinical evaluation involve differentiating it from pseudogynecomastia and ruling out male breast carcinoma. A selective laboratory and radiological work-up should follow to identify the underlying cause. Pubertal gynecomastia resolves spontaneously in the majority of adolescents, and hence reassurance and observation is regarded as the best approach. In adults with persistent painful gynecomastia, a short-term trial of medical therapy is an option that has shown good results. For chronic, bothersome gynecomastia, removal by plastic surgery is the treatment of choice.
- 1 September 2011
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 6 (5) , 723-730
Gynecomastia: incidence, causes and treatment
Gynecomastia is a benign proliferation of glandular tissue of the breast in males. It is common during three phases in the age distribution curve: the neonatal period, puberty and senescence. An imbalance between estrogen and androgen action at the level of breast tissue is believed to be the underlying pathophysiology. Initial steps in the clinical evaluation involve differentiating it from pseudogynecomastia and ruling out male breast carcinoma. A selective laboratory and radiological work-up should follow to identify the underlying cause. Pubertal gynecomastia resolves spontaneously in the majority of adolescents, and hence reassurance and observation is regarded as the best approach. In adults with persistent painful gynecomastia, a short-term trial of medical therapy is an option that has shown good results. For chronic, bothersome gynecomastia, removal by plastic surgery is the treatment of choice.